Cargando…
Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance
SIMPLE SUMMARY: Poor survival and treatment failure of patients with cancer are mainly due to resistance to therapy. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis...
Autores principales: | Machado, Susana, Silva, Andreia, De Sousa-Coelho, Ana Luísa, Duarte, Isabel, Grenho, Inês, Santos, Bruno, Mayoral-Varo, Victor, Megias, Diego, Sánchez-Cabo, Fátima, Dopazo, Ana, Ferreira, Bibiana I., Link, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763856/ https://www.ncbi.nlm.nih.gov/pubmed/33316942 http://dx.doi.org/10.3390/cancers12123689 |
Ejemplares similares
-
The Critical Role of TRIB2 in Cancer and Therapy Resistance
por: Mayoral-Varo, Victor, et al.
Publicado: (2021) -
Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3
por: Jimenez, Lucia, et al.
Publicado: (2021) -
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
por: Hill, Richard, et al.
Publicado: (2017) -
mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity
por: Jimenez, Lucia, et al.
Publicado: (2022) -
Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
por: Hill, Richard, et al.
Publicado: (2023)